We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Read MoreHide Full Article
Key Takeaways
Sanofi ended development of KT-474, opting to advance KT-485 into clinical studies next year.
KYMR signed a CDK2 degrader license deal with Gilead, gaining $85M upfront and up to $750M in milestones.
KYMR launched a $250M stock offering to fund clinical programs and general corporate purposes.
Kymera Therapeutics, Inc. (KYMR - Free Report) has announced that partner Sanofi (SNY - Free Report) will not advance the development of lead IRAK4 degrader KT-474.
This setback was somewhat offset by KYMR’s announcement of an exclusive option and license agreement with biotech giant Gilead Sciences, Inc. (GILD - Free Report) .
Kymera also commenced an underwritten public offering worth $250.0 million of its common stock.
The stock was down 1.4% on June 25 and dropped 6.91% in after-market trading, probably due to the setback in Sanofi’s partnership and dilution of equity.
Year to date, shares of KYMR have gained 15.5% against the industry’s decline of 2%.
Image Source: Zacks Investment Research
KYMR’s Update on Collaboration With Sanofi
Sanofi informed Kymera that it has selected KT-485/SAR447971, an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases, to advance into clinical studies.
The candidate was discovered by Kymera.
KT-485 is being prioritized for development under the companies’ existing IRAK4 collaboration following extensive preclinical work supporting its robust development potential. The candidate is expected to advance into early-stage testing next year.
Consequently, Sanofi has decided to let go of KT-474, which was being evaluated for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD) in two phase IIb dose-ranging studies.
Sanofi will not develop KT-474 any further. The company has also decided to exercise its participation election right for the IRAK4 target under the terms of the collaboration agreement. Per the agreement, Kymera achieved a $20 million milestone in the second quarter of 2025 (related to preclinical activities associated with KT-485).
Kymera is eligible to receive up to $975 million in potential clinical, regulatory, and commercial milestones related to KT-485, including an additional milestone upon the initiation of phase I clinical testing.
Kymera Therapeutics, Inc. Price, Consensus and EPS Surprise
Kymera entered into an exclusive option and license agreement with Gilead to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, in breast cancer and other solid tumors.
Per the companies, CDK2-directed MGDs are a new type of drug designed to remove CDK2, a key contributor in tumor growth, rather than just inhibiting its function.
Under the terms of the agreement, Kymera will receive an upfront payment of $85 million and potential option exercise payments. The total payments will range up to $750 million.
Kymera may also receive tiered royalties ranging from high single-digit to mid-teens on net product sales under the collaboration. While Kymera will lead all research activities for the CDK2 program, Gilead will have global rights to develop, manufacture and commercialize all products resulting from the collaboration if the latter exercises its option to exclusively license the program.
KYMR Issues Shares
Concurrent with these business updates, Kymera announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock.
Kymera intends to use the net proceeds from the offering to continue advancing its pipeline of preclinical and clinical degrader programs, which are designed to address large patient populations with significant needs and clear commercial opportunities. The proceeds will also be used for working capital and other general corporate purposes.
Our Take
While the oncology deal with GILD looks promising and the subsequent influx of cash is positive, investors were disappointed with the update from Sanofi.
Sanofi has decided to advance preclinical IRAK4 degrader KT-485 rather than advancing KT-474, which had moved to phase IIb studies in late 2023.
The move definitely delays milestone payments for Kymera that could have been achieved on the potential approval of KT-474.
Image: Bigstock
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Key Takeaways
Kymera Therapeutics, Inc. (KYMR - Free Report) has announced that partner Sanofi (SNY - Free Report) will not advance the development of lead IRAK4 degrader KT-474.
This setback was somewhat offset by KYMR’s announcement of an exclusive option and license agreement with biotech giant Gilead Sciences, Inc. (GILD - Free Report) .
Kymera also commenced an underwritten public offering worth $250.0 million of its common stock.
The stock was down 1.4% on June 25 and dropped 6.91% in after-market trading, probably due to the setback in Sanofi’s partnership and dilution of equity.
Year to date, shares of KYMR have gained 15.5% against the industry’s decline of 2%.
Image Source: Zacks Investment Research
KYMR’s Update on Collaboration With Sanofi
Sanofi informed Kymera that it has selected KT-485/SAR447971, an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases, to advance into clinical studies.
The candidate was discovered by Kymera.
KT-485 is being prioritized for development under the companies’ existing IRAK4 collaboration following extensive preclinical work supporting its robust development potential. The candidate is expected to advance into early-stage testing next year.
Consequently, Sanofi has decided to let go of KT-474, which was being evaluated for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD) in two phase IIb dose-ranging studies.
Sanofi will not develop KT-474 any further. The company has also decided to exercise its participation election right for the IRAK4 target under the terms of the collaboration agreement. Per the agreement, Kymera achieved a $20 million milestone in the second quarter of 2025 (related to preclinical activities associated with KT-485).
Kymera is eligible to receive up to $975 million in potential clinical, regulatory, and commercial milestones related to KT-485, including an additional milestone upon the initiation of phase I clinical testing.
Kymera Therapeutics, Inc. Price, Consensus and EPS Surprise
Kymera Therapeutics, Inc. price-consensus-eps-surprise-chart | Kymera Therapeutics, Inc. Quote
More on KYMR’s License Deal With GILD
Kymera entered into an exclusive option and license agreement with Gilead to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, in breast cancer and other solid tumors.
Per the companies, CDK2-directed MGDs are a new type of drug designed to remove CDK2, a key contributor in tumor growth, rather than just inhibiting its function.
Under the terms of the agreement, Kymera will receive an upfront payment of $85 million and potential option exercise payments. The total payments will range up to $750 million.
Kymera may also receive tiered royalties ranging from high single-digit to mid-teens on net product sales under the collaboration. While Kymera will lead all research activities for the CDK2 program, Gilead will have global rights to develop, manufacture and commercialize all products resulting from the collaboration if the latter exercises its option to exclusively license the program.
KYMR Issues Shares
Concurrent with these business updates, Kymera announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock.
Kymera intends to use the net proceeds from the offering to continue advancing its pipeline of preclinical and clinical degrader programs, which are designed to address large patient populations with significant needs and clear commercial opportunities. The proceeds will also be used for working capital and other general corporate purposes.
Our Take
While the oncology deal with GILD looks promising and the subsequent influx of cash is positive, investors were disappointed with the update from Sanofi.
Sanofi has decided to advance preclinical IRAK4 degrader KT-485 rather than advancing KT-474, which had moved to phase IIb studies in late 2023.
The move definitely delays milestone payments for Kymera that could have been achieved on the potential approval of KT-474.
Kymera currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.